Dyne is eyeing an accelerated approval filing for DYNE-251 in early 2026 that would pit the asset against Sarepta’s Exondys ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Avidity Biosciences (RNA) announced positive del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular ...

Avidity Biosciences Inc. says will submit an application for accelerated approval to the FDA for del-zota before the end of ...

Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its target price lowered by Scotiabank from $105.00 to $80.00 in a ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

The Phase I/II Deliver trial sought to establish the impact of DYNE-251 on several mobility-related endpoints, seeing an ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report)’s stock price traded down 4% during trading on Thursday after ...

Learn more about whether PTC Therapeutics, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Taiho is parting with $400 million upfront for Araris, a spin-off from the Paul-Scherrer-Institute in Zurich, Switzerland, ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...